The headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street es...

U.S.-based drug distributor McKesson raised its annual profit forecast on Wednesday, banking on strong demand for specialty medicines.

McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Evaluate the expected performance of McKesson (MCK) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metr...

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

McKesson (MCK) is seeking buyers for the Canadian Rexall Pharmacy Group. The business is currently amid its second round of offers, with no set deadline for submissions.

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

McKesson Corp is planning to sell Canadian drugstore chain Rexall Pharmacy Group, a source familiar with the process told Reuters on Friday, seven years after the U.S. drug distributor bought the b...

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2024 financial results after market close on Wednesday, February 7, 2024. The company will hos...

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PNH.

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for desmoid tumors.

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for breast cancer.

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for mCRC.

McKesson's (MCK) second-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.

While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics co...